摘要
目的 提高难治性中线外周T细胞淋巴瘤 (MPTCL)的疗效。方法 左旋门冬酰胺酶 (L ASP)组为 11例难治性MPTCL患者 ,给予L ASP为主的挽救化疗 (由L ASP、长春新碱和地塞米松组成 )。对照组为 10例难治性MPTCL患者 ,给予不含L ASP的联合化疗。观察比较两组的有效率和 2年生存率。结果 有效 (完全缓解加部分缓解 )率L ASP组为 6 3 .6 % ,对照组为 10 .0 % (P <0 .0 5 )。 2年生存率L ASP组为 45 .5 % ,对照组为 0 (P <0 .0 5 )。本组L ASP治疗的不良反应主要表现为白细胞减少、血清胆红素升高和高血糖症。结论 L ASP为主的挽救化疗可能提高难治性MPTCL的疗效和 2年生存率 ,值得进一步研究。
Objective To improve the treatment outcome of refractory midline peripheral T cell lymphoma (MPTCL). Method Eleven patients with refractory MPTCL received salvage chemotherapy consisting of L asparaginase(L ASP), vincristine and dexamethosone (L ASP group), and 10 patients received combined chemotherapy without L ASP(control group). The response rates and 2 year survival rates were observed. Results Response rates were 63 6% for L ASP group and 10.0% for control group (P<0.05), and 2 year survival rates were 45 5% and 0 (P<0.05), respectively. The major side effects of L ASP were leukocytopenia, elevation of serum bilirubin and hyperglycemia. Conclusion The L ASP based salvage chemotherapy improved the response rate and 2 year survival rate of the patients with refractory MPTCL.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2000年第11期577-579,共3页
Chinese Journal of Hematology
